Jul

2011

Aduro Biotech, Inc.: Series B $19.2M

Posted in I - Series B, Q - 2Q11, R - WEST, X - Antiinfective, X - Oncology, X - Vaccines, XX - CA

Aduro Biotech (Berkeley, CA) a clinical-stage therapeutic immunotherapy vaccine company focused on cancer and infectious disease, closed a $19.2M Series B financing. Participants include Morningside Ventures.

Apr

2011

Vaximm, AG: Series B $8M

Posted in I - Series B, Q - 1Q11, R - INTERNATIONAL, X - Immunology, X - Oncology, X - Vaccines

Vaximm (Switzerland) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for various solid tumors, closed a $8M Series B financing. Participants include BB Biotech Ventures, Sunstone Capital, Merck Serono Ventures and BioMedPartners.

Apr

2011

Kite Pharma, Inc.: Series A $15M

Posted in I - Series A, Q - 1Q11, R - WEST, X - Immunology, X - Oncology, X - Vaccines

Kite Pharma (Los Angeles, CA) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for renal cell carcinoma and hepatocellular carcinoma, closed a $15M Series A financing. Participants include TPG Capital.

Feb

2011

Genocea Biosciences, Inc.: Series B $35M

Posted in I - Series B, Q - 1Q11, R - NORTH EAST, X - Vaccines, XX - MA

Genocea Biosciences (Cambridge, MA) a preclinical-stage therapeutic vaccine developer focused on chlamydia trachomatis, streptococcus pneumonia and herpes simplex virus type 2 infections, closed a $35M Series B financing. Participants include Johnson & Johnson Dev Corp., Skyline Ventures, MP Healthcare Management, SR One, Auriga Partners, Cycad Group, Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture [...]

Oct

2010

Immune Design Corp.: Series B $32M

Posted in I - Series B, Q - 3Q10, R - NORTH WEST, X - Oncology, X - Vaccines, XX - WA

Immune Design (Seattle, WA) a development-stage therapeutic vaccine company focused on oncology and infectious disease, closed a $32M Series B financing. Participants include ProQuest Investments, Column Group, Versant Ventures and Alta Partners.

Sep

2010

Immatics Biotechnologies, GmbH: Series C $71M

Posted in I - Series C, Q - 3Q10, R - INTERNATIONAL, X - Immunology, X - Oncology, X - Vaccines

Immatics Biotechnologies (Germany) a clinical-stage biotechnology company focused on therapeutic vaccines against renal and colorectal cancers, closed a $71M Series C financing. Participants include dievini Hopp Biotech, Wellington Partners and MIG Verwaltungs.

Sep

2010

Okairos, AG: Series B $20.8M

Posted in I - Series B, Q - 3Q10, R - INTERNATIONAL, X - HIV, X - Hepatitis C, X - Influenza, X - Malaria, X - Vaccines

Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.

Aug

2010

Visterra, Inc.: Series A $6M

Posted in I - Series A, Q - 3Q10, R - NORTH WEST, X - Antiviral, X - Influenza, X - Vaccines, XX - MA

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Jul

2010

Liquidia Technologies, Inc.: Series C $5M

Posted in I - Series C, Q - 2Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

May

2010

CureVac, GmbH: Series C $34.9M

Posted in I - Series C, Q - 2Q10, R - INTERNATIONAL, X - Oncology, X - Vaccines, X - mRNA

CureVac (Germany) a clinical-stage biopharmaceutical companies focused on prophylactic and therapeutic vaccines for the treatment of prostate and non-small cell lung cancer, closed a $34.9M Series C financing. Participants include dievini Hopp BioTech Holding.

Apr

2010

Liquidia Technologies, Inc.: Series C $13M

Posted in I - Series C, Q - 1Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Apr

2010

Juvaris BioTherapeutics, Inc.: Series B $12.5M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Influenza, X - Leukemia, X - Vaccines, XX - CA

Juvaris BioTherapeutics (Burlingame, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing, bringing the total round to $25M. Participants include Kleiner Perkins Caufield & Byers, SV Life Sciences and an undisclosed corporate partner.

Apr

2010

GlobeImmune, Inc.: Series E $17.5M

Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

« Previous Entries

to top of page...